Trials begin testing a longer-lasting therapy for diabetic eye disease, as researchers push to reduce treatment burden and protect vision.
Clinical breakthroughs begin with the first patient receiving a dose. That moment has now arrived for US-based biopharma EyePoint Pharmaceuticals, which has announced that the first patients have been dosed in two global Phase 3 clinical trials testing its experimental therapy DURAVYU for diabetic macular edema (DME), a major cause of vision loss among people living with diabetes [1].
The trials, called COMO and CAPRI, represent the final stage of testing before regulators decide whether a drug could eventually reach the market. If the results hold up, the therapy could change how one of the most common diabetic eye diseases is managed, not by replacing existing treatments entirely, but by potentially making them last longer.
This shift could matter far beyond ophthalmology clinics. In the world of longevity science, protecting eyesight is increasingly seen as essential to maintaining independence and quality of life as people age.
Diabetic macular edema develops when long-term high blood sugar damages tiny blood vessels in the retina. Over time, those vessels become leaky, allowing fluid to accumulate in the macula, the central part of the retina responsible for detailed vision.
The result is swelling that blurs sight. Everyday tasks like reading, driving or recognizing faces can slowly become more difficult.
Globally, around 28 million people are affected by the condition. As diabetes rates climb worldwide, that number is expected to grow, meaning more people could face the risk of vision loss during what should be their most productive years.
Current treatments typically involve injections that block a protein called VEGF, which contributes to abnormal blood vessel growth and leakage in the eye. These therapies can be effective, but they come with a demanding reality. Patients often need injections every few weeks or months. For a chronic disease that can last decades, that schedule can quickly become exhausting.
This is where EyePoint’s experimental therapy comes into play. Instead of delivering medication that fades quickly, DURAVYU is designed to release its drug slowly over time through a tiny insert injected into the eye. The goal is to provide treatment that could last around six months from a single dose.
“Dosing of the first patients in our two pivotal DME trials represents a significant milestone for EyePoint and DURAVYU – the only TKI in Phase 3 clinical trials for DME – and solidifies our leadership in sustained-release ocular drug delivery,” said Dr Ramiro Ribeiro, Chief Medical Officer of EyePoint.
Think of it as the difference between taking pain relievers every few hours versus using a long-acting patch that releases medication steadily throughout the day. In eye care, that kind of durability could mean fewer injections and fewer clinic visits. For patients managing diabetes, that convenience could translate into something even more important: consistency.
Even with today’s therapies, many patients continue to struggle with persistent disease activity. Dr David Eichenbaum, who serves as the Director of Research for Retina Vitreous Associates and a Principal Investigator for the CAPRI trial, highlighted a significant gap in the treatment landscape for Diabetic Macular Edema (DME). He observed that:
- Current treatments are insufficient. There is an urgent requirement for therapies that offer greater durability and more distinct mechanisms of action.
- The burden is too high. The prevailing standard of care places an excessive strain on patients, many of whom are still of working age.
- Unmet clinical needs persist. Existing anti-VEGF loading doses fail to fully manage the condition, leaving up to two-thirds of patients with ongoing active disease.
That highlights a reality physicians often see in practice. Treating retinal disease is rarely a one-and-done intervention; it is an ongoing balancing act between controlling inflammation, reducing fluid buildup and preserving the delicate structures of the eye.
DURAVYU attempts to tackle several of these biological drivers at once by targeting pathways linked to blood-vessel leakage and inflammation – two forces that drive the swelling seen in DME.
Early clinical studies suggested the therapy could stabilize vision and retinal anatomy with longer intervals between treatments, though larger trials are needed to confirm the findings.
What happens next? The Phase 3 program will enroll approximately 240 patients per trial across multiple countries. Participants will receive either DURAVYU or aflibercept, a widely used current treatment, allowing researchers to compare outcomes directly.
Patients receiving DURAVYU will be re-dosed every six months, and researchers will monitor changes in visual acuity, retinal health and overall safety.
If the therapy performs well, the implications could reach two major ophthalmology markets: diabetic macular edema and wet age-related macular degeneration, another leading cause of blindness that EyePoint is also targeting.
Topline data from the DME trials is expected in the second half of 2027.
Longevity.Technology: Preserving vision is not merely about avoiding blindness; it is about protecting autonomy. Losing sight can accelerate many of the very health declines longevity science is trying to prevent. As people live longer, chronic conditions like diabetes will increasingly shape the aging experience. Therapies that reduce treatment burden while preserving function may therefore play a quiet but important role in extending healthspan.
DURAVYU is still an investigational therapy, and clinical trials are designed precisely because promising ideas do not always translate into real-world success. But the concept behind it – longer-lasting treatments that fit more seamlessly into patients’ lives – is an important shift happening across medicine.
The goal is increasingly becoming about helping people live longer lives without losing the abilities that make those years meaningful, including the ability to see them clearly.
